Raymond James Financial Services Advisors Inc. Increases Stake in Alexion Pharmaceuticals, Inc. (ALXN)

Share on StockTwits

Raymond James Financial Services Advisors Inc. grew its position in shares of Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) by 2.5% in the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 22,298 shares of the biopharmaceutical company’s stock after buying an additional 548 shares during the quarter. Raymond James Financial Services Advisors Inc.’s holdings in Alexion Pharmaceuticals were worth $2,171,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other institutional investors have also recently made changes to their positions in the company. NuWave Investment Management LLC lifted its holdings in Alexion Pharmaceuticals by 851.9% in the 4th quarter. NuWave Investment Management LLC now owns 514 shares of the biopharmaceutical company’s stock worth $50,000 after purchasing an additional 460 shares during the last quarter. Benjamin F. Edwards & Company Inc. acquired a new stake in Alexion Pharmaceuticals in the 4th quarter worth approximately $68,000. We Are One Seven LLC acquired a new stake in Alexion Pharmaceuticals in the 4th quarter worth approximately $79,000. Shine Investment Advisory Services Inc. lifted its holdings in Alexion Pharmaceuticals by 114.1% in the 4th quarter. Shine Investment Advisory Services Inc. now owns 897 shares of the biopharmaceutical company’s stock worth $87,000 after purchasing an additional 478 shares during the last quarter. Finally, Pearl River Capital LLC acquired a new stake in Alexion Pharmaceuticals in the 4th quarter worth approximately $126,000. Institutional investors and hedge funds own 93.24% of the company’s stock.

Shares of NASDAQ:ALXN opened at $134.88 on Friday. Alexion Pharmaceuticals, Inc. has a fifty-two week low of $92.56 and a fifty-two week high of $140.77. The firm has a market capitalization of $30.14 billion, a price-to-earnings ratio of 19.02, a P/E/G ratio of 1.00 and a beta of 1.55. The company has a current ratio of 2.88, a quick ratio of 2.48 and a debt-to-equity ratio of 0.31.

Alexion Pharmaceuticals (NASDAQ:ALXN) last posted its quarterly earnings data on Monday, February 4th. The biopharmaceutical company reported $2.14 EPS for the quarter, topping analysts’ consensus estimates of $1.60 by $0.54. The company had revenue of $1.13 billion for the quarter, compared to analyst estimates of $1.06 billion. Alexion Pharmaceuticals had a return on equity of 18.15% and a net margin of 1.88%. The business’s revenue was up 24.1% on a year-over-year basis. During the same quarter in the previous year, the firm earned $1.48 earnings per share. As a group, research analysts predict that Alexion Pharmaceuticals, Inc. will post 8.51 EPS for the current fiscal year.

ALXN has been the subject of a number of research analyst reports. BidaskClub lowered Alexion Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Thursday, February 7th. Credit Suisse Group restated a “buy” rating and set a $156.00 price objective on shares of Alexion Pharmaceuticals in a research report on Friday, December 21st. Raymond James reiterated a “buy” rating on shares of Alexion Pharmaceuticals in a research report on Sunday, December 30th. Zacks Investment Research cut Alexion Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Tuesday, February 12th. Finally, Cowen reiterated a “buy” rating and issued a $165.00 price target on shares of Alexion Pharmaceuticals in a research report on Wednesday. Five research analysts have rated the stock with a hold rating and fourteen have issued a buy rating to the stock. The stock presently has an average rating of “Buy” and a consensus price target of $160.75.

In other Alexion Pharmaceuticals news, CEO Ludwig Hantson sold 3,244 shares of the business’s stock in a transaction on Monday, December 31st. The stock was sold at an average price of $95.85, for a total value of $310,937.40. Following the transaction, the chief executive officer now owns 150,696 shares of the company’s stock, valued at $14,444,211.60. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website. Also, CAO Daniel Bazarko sold 2,000 shares of the business’s stock in a transaction on Thursday, February 14th. The stock was sold at an average price of $126.00, for a total value of $252,000.00. Following the completion of the transaction, the chief accounting officer now directly owns 5,020 shares in the company, valued at approximately $632,520. The disclosure for this sale can be found here. In the last three months, insiders sold 8,488 shares of company stock worth $873,875. Insiders own 4.35% of the company’s stock.

ILLEGAL ACTIVITY NOTICE: This piece was reported by Ticker Report and is the sole property of of Ticker Report. If you are accessing this piece on another publication, it was copied illegally and republished in violation of U.S. and international copyright & trademark law. The legal version of this piece can be viewed at https://www.tickerreport.com/banking-finance/4223640/raymond-james-financial-services-advisors-inc-increases-stake-in-alexion-pharmaceuticals-inc-alxn.html.

Alexion Pharmaceuticals Profile

Alexion Pharmaceuticals, Inc, a biopharmaceutical company, develops and commercializes various therapeutic products. The company offers ULTOMIRIS (ALXN1210/ravulizumab-cwvz), a monoclonal antibody for the treatment of paroxysmal nocturnal hemoglobinuria (PNH), a genetic blood disorder; and Soliris (eculizumab), a monoclonal antibody for the treatment of PNH, atypical hemolytic uremic syndrome (aHUS), and generalized myasthenia gravis.

See Also: Dow Jones Industrial Average (DJIA)

Want to see what other hedge funds are holding ALXN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN).

Institutional Ownership by Quarter for Alexion Pharmaceuticals (NASDAQ:ALXN)

Receive News & Ratings for Alexion Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alexion Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.



Latest News

Nextera Energy Partners  Issues Quarterly  Earnings Results, Misses Estimates By $0.90 EPS
Nextera Energy Partners Issues Quarterly Earnings Results, Misses Estimates By $0.90 EPS
First Industrial Realty Trust  Updates FY19 Earnings Guidance
First Industrial Realty Trust Updates FY19 Earnings Guidance
Wanchain Price Down 11.3% Over Last 7 Days
Wanchain Price Down 11.3% Over Last 7 Days
Hudson Technologies, Inc.  Receives $4.00 Consensus Target Price from Analysts
Hudson Technologies, Inc. Receives $4.00 Consensus Target Price from Analysts
Companhia Brasileira de Distribuicao  Lifted to “Strong-Buy” at Zacks Investment Research
Companhia Brasileira de Distribuicao Lifted to “Strong-Buy” at Zacks Investment Research
Guaranty Bancshares  Announces Quarterly  Earnings Results
Guaranty Bancshares Announces Quarterly Earnings Results


© 2006-2019 Ticker Report